Loading
A phase 1/2 trial of Camizestrant, Ribociclib, Palbociclib in ovarian cancer, run by AstraZeneca, now recruiting.
A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors is a phase 1/2 interventional study registered as NCT06188520 by AstraZeneca, with 564 participants planned, started 2023-12-05 and due to reach its primary completion in 2027-08-04. Interventions recorded: AZD8421, Camizestrant, Ribociclib, Palbociclib, Abemaciclib. Conditions listed: ER+ HER2- Advanced Breast Cancer, High-grade Serous Ovarian Cancer (HGSOC). No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Camizestrant, Ribociclib, Abemaciclib, Palbociclib.
Shares Ribociclib, Abemaciclib, Palbociclib, AstraZeneca.
Shares Ribociclib, Abemaciclib, Palbociclib, Ovarian cancer.
Shares Ribociclib, Abemaciclib, Palbociclib.
Shares Camizestrant, Palbociclib, AstraZeneca.
Shares Ribociclib, Abemaciclib, Palbociclib.
Shares Camizestrant, Ribociclib, AstraZeneca.
Shares Ribociclib, Abemaciclib, Palbociclib.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/